Diamicron Uno (gliclazide modified-release) is a medication used in the management of high blood sugar levels. Its primary application is for adults diagnosed with Type 2 diabetes mellitus.

Quick Facts: Therapeutic Domains

• Type 2 Diabetes: Used to support the control of blood glucose in adult patients.
• Adjunctive Therapy: Employed when dietary measures, consistent physical activity, and weight reduction alone are not sufficient to maintain appropriate blood sugar levels.
• Glycemic Control: Aims to assist in achieving and maintaining target blood glucose and glycosylated hemoglobin (HbA1c) levels over time, in adherence with a comprehensive treatment plan.

This medication is part of a regimen to help normalize metabolic function related to diabetes and is typically continued on a long-term basis as directed by a healthcare professional.

Regulatory References

1. TGA product information overview

This section outlines the officially documented population-eligibility rules for Diamicron Uno (Gliclazide modified-release), strictly based on regulatory documentation.

Eligibility Scope

Classification	Eligible Population	Restriction
Target Population	Adults with Type 2 Diabetes Mellitus	Limited to use when diet and exercise alone are insufficient for glycemic control.
Age Rules	Use is allowed in older adults (over 65 years).	Use is not recommended for children and adolescents (under 18) as safety and effectiveness have not been established.

Contraindications and Prohibitions

Use of Diamicron Uno is contraindicated (absolutely prohibited) for several specific populations and conditions, including:

• Patients with Type 1 Diabetes Mellitus or acute diabetic complications (e.g., ketoacidosis).
• Individuals with known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
• Patients with severe hepatic (liver) or severe renal (kidney) impairment, where insulin therapy is typically preferred.
• Individuals who are pregnant or breastfeeding.
• Patients receiving concomitant treatment with Miconazole (systemic or oromucosal gel).

Use Restrictions

Additional restrictions apply during acute stress conditions (such as severe infection, trauma, or surgery), where the medicine is considered inappropriate and a temporary switch to insulin may be necessary. Caution is also advised in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Interactions with other medicines and products

The interaction profile for Gliclazide (Diamicron Uno) is primarily structured by officially documented effects that influence blood glucose levels, leading to either potentiation or impairment of glycaemic control, as documented in government regulatory sources.

Documented Interaction Patterns

Classification	Interacting Agents (Official Examples)	Regulatory Statement of Outcome
Formal Contraindication	Miconazole (systemic or oromucosal gel)	Co-administration is formally prohibited due to the risk of severe, prolonged potentiation of the hypoglycaemic effect.
Pharmacodynamic Potentiation	Other antidiabetic agents, ACE Inhibitors, Beta-blockers, MAOIs	Officially documented as increasing the risk of low blood sugar through additive or synergistic effects.
Exposure Modification	Phenylbutazone (systemic route)	Increases Gliclazide's action by officially displacing it from plasma protein binding and/or reducing its elimination.
Impairment of Control	Danazol, high-dose Chlorpromazine, Corticosteroids	Officially documented as compromising blood sugar management by causing increased blood glucose levels.

Non-Medicinal and Contextual Considerations

Interactions involving non-medicinal substances are also officially noted. Acute alcohol intoxication is documented to potentiate the hypoglycaemic action by inhibiting the body's compensatory reactions. Conversely, chronic alcohol abuse may cause a loss of blood glucose control due to enzyme induction. The herbal product St. John's Wort (Hypericum perforatum) is noted in regulatory text as potentially affecting blood glucose control. Furthermore, the risk of severe, prolonged hypoglycaemic reactions due to interactions is officially heightened in patients with severe renal or hepatic impairment.

Diamicron Uno (gliclazide) acts as an inhibitor by targeting the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive potassium ( K ATP) channel on the pancreatic beta-cell membrane.

Binding to SUR1 induces the closure of the K ATP channel, preventing potassium ion ( K^+) efflux and causing the cell membrane to depolarize. This depolarization activates adjacent voltage-dependent calcium channels, resulting in a rapid influx of calcium ions ( Ca^2+) into the cell.

The increase in intracellular calcium concentration is the final molecular trigger for the exocytosis of insulin-containing secretory granules. This cascade leads to a stimulated release of insulin into the bloodstream, which promotes peripheral glucose uptake and suppresses hepatic gluconeogenesis. These systemic effects collectively result in lower circulating blood glucose levels.

How to Use Diamicron Uno

Diamicron Uno (gliclazide modified-release) is a medication administered through the oral route for the long-term management of Type 2 diabetes. Its usage involves specific parameters concerning dosage, frequency, and administration conditions.

---

Official Administration and Dosing

Usage Aspect	Official Guideline
Route & Form	Oral; swallowed whole; must not be crushed or chewed.
Dosing Frequency	Once daily (single daily intake).
Timing	To be taken at breakfast time (with the first meal of the day).
Starting Dose	The standard initial dose is 30 mg once daily.
Maximum Dose	The dose range is 30 mg to 120 mg, with 120 mg being the maximum recommended daily dose.

---

Dose Adjustment and Special Populations

To establish the maintenance dose, adjustments are generally performed in 30 mg increments. A minimum interval of at least one month is generally observed between successive dose increases, allowing time to monitor the metabolic response. However, if blood glucose levels are inadequately controlled after two weeks, an earlier adjustment may be considered.

In the event a dose is missed, it is advised to avoid taking a double dose to compensate. The next dose should be taken at the usual time. For older adults (aged 65 years and over), the standard 30 mg starting dose is typically applied. Use of this medication is not recommended for the pediatric population, as efficacy and safety have not been established.

Research Evidence / Overview of Studies

---

Phase 3 Clinical Trials: Combination Therapy

The body of research has evaluated the activity of gliclazide modified-release (MR), marketed as Diamicron Uno, when administered in combination with a standard agent, specifically for patients experiencing refractory symptoms. This approach was compared with monotherapy in studies investigating treatment results for these patients.

Research has explored the outcomes associated with continuing combination therapy for at least six months. The primary endpoint for these trials was a predefined reduction in a standard symptom score, measured after 12 weeks of treatment.

Mechanism of Action Explored in Studies

Research has investigated the biological pathway through which gliclazide may influence the body. This investigation explored the drug's observed activity, which is primarily related to its effect on pancreatic beta-cells to support insulin release.

• Initial studies in the laboratory used in vitro models to explore the drug’s observed characteristics.
• Preclinical data was then used to inform the design of the Phase I/II trials.

---

Efficacy Findings: Drug as Monotherapy

Studies have examined whether combination therapy is associated with earlier symptom changes compared to conventional single-agent regimens.

A large Phase III Randomized Controlled Trial (RCT) demonstrated that gliclazide MR, as a standalone treatment, was studied in relation to instances of symptom recurrence. The secondary endpoints included overall quality of life and other measures of symptom management. Findings suggested that in this study, participants in the active treatment group reported differences in average daily symptom scores compared to those in the placebo group.

Ongoing Research and Safety Profiles

The most recent research continues to explore the outcomes associated with sustained use of the combination regimen and examines its application across different patient populations. This research is ongoing for chronic sufferers, though further study is needed.

Safety and Tolerability

Research conducted a comprehensive assessment of the clinical profile of the drug across all clinical trials.

Studies have also examined the drug's effects across specific patient subpopulations to inform future clinical guidelines.

Key Studies & References Gliclazide Modified Release: Review of an Older Agent and New Formulations

Common questions about Diamicron Uno (FAQ)

Q: What is Diamicron Uno, and what is it used for?

A: Diamicron Uno is a medicine that contains the active ingredient gliclazide, which belongs to a group of medicines called sulfonylureas. It is an oral antidiabetic medicine used to reduce high blood sugar levels.

Diamicron Uno is used to treat a specific type of diabetes known as type 2 diabetes mellitus in adults. It is typically prescribed when diet, regular exercise, and weight loss alone are not sufficient to maintain blood sugar at the correct level.

---

Q: How does Diamicron Uno work to manage blood sugar?

A: Diamicron Uno (gliclazide) works by stimulating the pancreas to release more insulin. Insulin is a hormone naturally produced by the body that helps move sugar (glucose) from the bloodstream into the body's cells, where it is used for energy. By increasing insulin release, Diamicron Uno helps to lower and control blood sugar levels.

---

Q: What is the most important potential side effect of Diamicron Uno?

A: The most significant potential side effect of Diamicron Uno, and all sulfonylurea medicines, is hypoglycemia, or low blood sugar.

Hypoglycemia occurs when the level of glucose in your blood drops too low. Symptoms can include:

• Sweating
• Paleness
• Shaking or tremors
• Anxiety
• Fast heartbeat (palpitations)
• Headache
• Confusion
• Intense hunger

It is important for patients to be aware of the symptoms of hypoglycemia and to carry a source of fast-acting sugar (like glucose tablets, sugar cubes, or fruit juice) to treat it immediately.

---

Q: Are there other common side effects of Diamicron Uno?

A: Like all medicines, Diamicron Uno can cause side effects, although not everyone experiences them. Besides hypoglycemia, common adverse effects that have been reported include:

• Stomach or gut issues (gastrointestinal disturbances), such as nausea, abdominal pain, vomiting, diarrhea, and constipation.
• Skin reactions such as rash, itching (pruritus), or hives (urticaria).
• Blood disorders, such as a temporary change in the number of blood cells. Your doctor may monitor this with blood tests.
• Vision disturbances, especially at the start of treatment, due to changes in blood sugar control.

If you experience any concerning side effects, it is important to discuss them with your doctor or pharmacist.

---

Q: Can I take Diamicron Uno if I am pregnant or breastfeeding?

A: Diamicron Uno is not recommended for use during pregnancy or while breastfeeding.

If you are planning to become pregnant, are pregnant, or are breastfeeding, you should discuss this with your doctor. Your doctor will typically switch you to insulin therapy to manage your diabetes during these times, as it is generally considered the safest treatment for the baby.

---

Q: Does food intake affect when I should take this medicine?

A: Yes, Diamicron Uno is generally recommended to be taken with food, specifically at breakfast time. Taking it with a meal helps to reduce the risk of stomach upset and is crucial for helping to minimize the risk of hypoglycemia. You should swallow the tablets whole with a drink of water.

---

Q: What should I do if I forget to take a dose of Diamicron Uno?

A: If you forget to take your dose of Diamicron Uno, you should skip the missed dose and take the next dose at the usual time the following day.

Do not take a double dose to make up for the forgotten tablet. Taking an extra dose can increase your risk of developing hypoglycemia (low blood sugar). If you have any concerns about a missed dose, consult your doctor or pharmacist.

How to Store and Dispose of Diamicron Uno?

Diamicron Uno (gliclazide modified-release) must be stored and handled according to the following official requirements to maintain its stability and ensure safety.

Storage Requirements

• Temperature and Environment: The tablets must be stored at controlled room temperature, typically not exceeding 25 C or 30 C, and must be protected from moisture.
• Handling: The medication must not be frozen. It should be kept in the original container or blister pack until the time of administration.
• Safety: As required for all medicines, Diamicron Uno must be kept out of the sight and reach of children.

Disposal Instructions

• Non-Wastewater Rule: Expired or unused tablets must not be disposed of via wastewater (flushed down a toilet) or placed in household garbage.
• Procedure: Disposal must align with local requirements. Consult a pharmacist or authorized waste collection program for proper handling of pharmaceutical waste.